This primer aims to provide IMF macroeconomists with the essential information they need to address issues concerning health sector policy, particularly when they have significant macroeconomic implications. Such issues can also affect equity and growth and are fundamental to any strategy of...

This primer aims to provide IMF macroeconomists with the essential information they need in situations where they must address issues concerning health sector policy and when they have significant macroeconomic implications. Such issues can also affect equity and growth and are fundamental to...

The aim of this study is to address the challenges of using cost-effectiveness analysis (CEA) by decision-makers in rationalizing health care public spending. Firstly, it presents a brief literature review on the necessity of using cost-effectiveness analysis. Also, the paper focuses on ways of...

In a recent work by Dolan and Edlin it is concluded that no link can be established between cost-benefit analysis (CBA) and cost-effectiveness analysis (CEA). However, the conclusion seems to depend rather heavily on what is understood by a link between CBA and CEA as well as on the exact...

The Water Framework Directive requires EU Member States to analyse economic impacts of the Directive's implementation. To reach a "good status", instruments have to be judged according to their cost-effectiveness. We evaluate costs and effects of measures to reduce nitrate emission of Austrian...

This report presents a computer model for evaluating the cost-effectiveness (CE) of Hormone Replacement Therapy (HRT). The model is an extension of a previous model and includes also the risk of spine and wrist fracture. New Swedish data on risk of coronary heart disease and related mortality...

At the present time no widely accepted temporal emissions path for greenhouse gases has been developed and adopted at either a country or a global level. What does exist is a set of nearterm, country-level emissions targets associated with the first commitment period of the Kyoto Protocol and a...

Federal agencies in the United States are required to prepare regulatory impact analyses (RIAs) for every major regulatory action they undertake. Increasingly, other OECD countries are imposing similar requirements. However, there has been little examination of the quality of these documents or...

We consider the problem of assessing new and existing technologies for their cost-effectiveness in the case where data on both costs and effects are available from a clinical trial, and we address it by means of the cost-effectiveness acceptability curve. The main difficulty in these analyses is...